3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding.

Abnormal proliferation mediated by disruption of the normal cell cycle mechanisms is a hallmark of virtually all cancer cells. Compounds targeting complexes between cyclin-dependent kinases (CDK) and cyclins, such as CDK2/cyclin A and CDK2/cyclin E, and inhibiting their kinase activity are regarded as promising antitumor agents to complement the existing therapies. From a high-throughput screening effort, we identified a new class of CDK2/cyclin A/E inhibitors. The hit-to-lead expansion of this class is described. X-ray crystallographic data of early compounds in this series, as well as in vitro testing funneled for rapidly achieving in vivo efficacy, led to a nanomolar inhibitor of CDK2/cyclin A (N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(2-naphthyl)acetamide (41), PNU-292137, IC50 = 37 nM) with in vivo antitumor activity (TGI > 50%) in a mouse xenograft model at a dose devoid of toxic effects.

[1]  V. Ling.  Multidrug resistance: molecular mechanisms and clinical relevance , 1997, Cancer Chemotherapy and Pharmacology.

[2]  R. Pepperkok,et al.  Cyclin A is required at two points in the human cell cycle. , 1992, The EMBO journal.

[3]  E. Sausville,et al.  Flavopiridol, a Novel Cyclin-Dependent Kinase Inhibitor, in Clinical Development , 2002, The Annals of pharmacotherapy.

[4]  R. Chetty,et al.  Cyclin E in human cancers , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  Jiri Bartek,et al.  Centrosome duplication in mammalian somatic cells requires E2F and Cdk2–Cyclin A , 1999, Nature Cell Biology.

[6]  W. Kaelin,et al.  Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[7]  B. Kennedy,et al.  NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. , 2000, Genes & development.

[8]  H. F. Horn,et al.  Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.

[9]  W. Wilson,et al.  CHAPTER 15 – TUMOR CELL CULTURES IN DRUG DEVELOPMENT , 2002 .

[10]  G J Kleywegt,et al.  Phi/psi-chology: Ramachandran revisited. , 1996, Structure.

[11]  D. Livingston,et al.  Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint , 1995, Cell.

[12]  F. H. Espinoza,et al.  Control of eukaryotic cell cycle progression by phosphorylation of cyclin-dependent kinases. , 1998, The cancer journal from Scientific American.

[13]  Anne Fernandez,et al.  Cyclin a is required for the onset of DNA replication in mammalian fibroblasts , 1991, Cell.

[14]  R Pepperkok,et al.  Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts , 1993, The Journal of cell biology.

[15]  N. Pavletich.  Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. , 1999, Journal of molecular biology.

[16]  C. Peng,et al.  Cyclin A/CDK2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation , 1994, Molecular and cellular biology.

[17]  Frank McCormick,et al.  Proliferation of cancer cells despite CDK2 inhibition. , 2003, Cancer cell.

[18]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[19]  Peter D. Adams,et al.  HIRA, the Human Homologue of Yeast Hir1p and Hir2p, Is a Novel Cyclin-cdk2 Substrate Whose Expression Blocks S-Phase Progression , 2001, Molecular and Cellular Biology.

[20]  B. Dynlacht,et al.  Differential regulation of E2F transactivation by cyclin/cdk2 complexes. , 1994, Genes & development.

[21]  R. Weinberg,et al.  The role of RB in cell cycle control. , 1995, Progress in cell cycle research.

[22]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[23]  Kornelia Polyak,et al.  Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex , 1995, Nature.

[24]  S. Kim,et al.  Purification and crystallization of human cyclin-dependent kinase 2. , 1993, Journal of molecular biology.

[25]  M. Kitagawa,et al.  Phosphorylation of E2F-1 by cyclin A-cdk2. , 1995, Oncogene.

[26]  J. Nevins,et al.  Distinct roles for E2F proteins in cell growth control and apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Barbacid,et al.  To cycle or not to cycle: a critical decision in cancer , 2001, Nature reviews. Cancer.

[28]  C. Sherr.  Cancer Cell Cycles , 1996, Science.

[29]  J. Slingerland,et al.  The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. , 1999, Annual review of medicine.

[30]  J. Cheville,et al.  p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. , 1999, The American journal of pathology.

[31]  W. Seelen,et al.  Selective ring N-protection of aminopyrazoles , 2003 .

[32]  L. Johnson,et al.  Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 , 1997, Nature Structural Biology.

[33]  Nikolai Zhelev,et al.  In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R‐roscovitine) , 2002, International journal of cancer.

[34]  H. F. Horn,et al.  Specific Phosphorylation of Nucleophosmin on Thr199 by Cyclin- dependent Kinase 2-Cyclin E and Its Role in Centrosome Duplication* , 2001, The Journal of Biological Chemistry.

[35]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[36]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[37]  P. Pandolfi,et al.  Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27Kip1 Activity , 1999, Molecular and Cellular Biology.